McKesson Corporation with ticker code (MCK) have now 12 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 450 and 376 and has a mean target at $429.75. Given that the stocks previous close was at $354.48 and the analysts are correct then there would likely be a percentage uptick in value of 21.2%. It’s also worth noting that there is a 50 day moving average of $357.62 and the 200 day MA is $357.40. The market cap for the company is $49,279m. Find out more information at: https://www.mckesson.com
The potential market cap would be $59,743m based on the market consensus.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
The company has a dividend yield of 0.61% with the ex dividend date set at 28-2-2023 (DMY).
Other points of data to note are a P/E ratio of 16.41, revenue per share of 1906.41 and a 4.17% return on assets.
